Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma.
Kazuki YanagidaTaketo KawaiToyoshi SeitoKensuke MatsumotoTomoyuki KanekoTohru NakagawaPublished in: IJU case reports (2024)
This is the first report of the development of myelodysplastic syndrome during enfortumab vedotin therapy in a clinical setting. Although rare, myelodysplastic syndrome can occur during enfortumab vedotin therapy.